The FDA’s review of drug and biological products in this medication class is critical, as a brain impairment impacts between 6.5% and 7.9% of adults in the United States.
The 2016 National Health Interview Survey found that high-impact chronic pain and chronic pain that does not limit major life activities were linked to various physical and mental conditions.